3,4-dihydro-8-ethyl-6-(4-(N-methyl-2-phenylethyl)amino-1-piperidinyl)carbonyl-2(1H)-quinolinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3,4-dihydro-8-ethyl-6-(4-(N-methyl-2-phenylethyl)amino-1-piperidinyl)carbonyl-2(1H)-quinolinone
• 英文别名: 8-ethyl-6-[4-[methyl(2-phenylethyl)amino]piperidine-1-carbonyl]-3,4-dihydro-1H-quinolin-2-one
• 化学式: C₂₆H₃₃N₃O₂
• 分子量: 419.567
• InChiKey: UXTJPMNSTVUPBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  52.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-乙基苯胺 在 palladium on activated charcoal 吡啶 、 三氯化铝 、 diethylphosphoryl cyanide 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 二硫化碳 、 水 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 氯苯 、 丙酮 为溶剂， 90.0 ℃ 、101.33 kPa 条件下， 反应 6.0h， 生成 3,4-dihydro-8-ethyl-6-(4-(N-methyl-2-phenylethyl)amino-1-piperidinyl)carbonyl-2(1H)-quinolinone
  参考文献：
  名称：

  Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives

  摘要：

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.

  DOI：

  10.1021/jm020597o

文献信息

• Novel Selective Hindlimb Vasodilators:  Synthesis and Biological Activity of 1-Acyl-4-aminopiperidine Derivatives
  作者：Shuji Teramoto、Michinori Tanaka、Hiroshi Shimizu、Takafumi Fujioka、Fujio Tabusa、Takashi Imaizumi、Kenji Yoshida、Hiroyuki Fujiki、Toyoki Mori、Takumi Sumida、Michiaki Tominaga

  DOI：10.1021/jm020597o

  日期：2003.7.1

  A series of 6-(4-amino-1-piperidinyl)carbonyl-2(1H)-quinolinones, and their open form derivatives, were synthesized and evaluated for their ability to stimulate femoral artery blood flow (FBF) in the canine hindlimb. All members of this series stimulated FBF, and subsequent experiments revealed that selected members of this series produced minimal changes in coronary blood flow or systemic blood pressure. Compound 25 was the most promising agent in this respect, and clinical trials are now ongoing to evaluate the effectiveness of this drug as a novel treatment for intermittent claudication and Raynaud's phenomenon.